Stock Analysis
- United States
- /
- Healthtech
- /
- NasdaqGS:CERT
Certara First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Certara (NASDAQ:CERT) First Quarter 2024 Results
Key Financial Results
- Revenue: US$96.7m (up 7.0% from 1Q 2023).
- Net loss: US$4.68m (down by 445% from US$1.36m profit in 1Q 2023).
- US$0.029 loss per share (down from US$0.009 profit in 1Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Certara Revenues Beat Expectations, EPS Falls Short
Revenue exceeded analyst estimates by 3.2%. Earnings per share (EPS) missed analyst estimates.
Looking ahead, revenue is forecast to grow 8.8% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare Services industry in the US.
Performance of the American Healthcare Services industry.
The company's shares are down 7.2% from a week ago.
Balance Sheet Analysis
Just as investors must consider earnings, it is also important to take into account the strength of a company's balance sheet. See our latest analysis on Certara's balance sheet health.
Valuation is complex, but we're helping make it simple.
Find out whether Certara is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NasdaqGS:CERT
Certara
Provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally.
Excellent balance sheet with reasonable growth potential.